Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Coronary Artery Disease
Interventions: VEST, Coronary artery bypass vein grafts; Device · Procedure
Lead sponsor: Vascular Graft Solutions Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 14
States / cities: Los Angeles, California • Fort Wayne, Indiana • Baltimore, Maryland + 9 more

Conditions: Progressive Supranuclear Palsy
Interventions: Tolfenamic Acid, Placebos; Drug
Lead sponsor: NeuroTau, Inc.; Other
Eligibility: 40 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Asthma
Interventions: RPT193, Placebo; Drug · Other
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 13
States / cities: San Jose, California • Stockton, California • Westminster, California + 9 more

Conditions: Thrombosis
Interventions: Rivaroxaban, Acetylsalicylic Acid; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 8 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 17
States / cities: Los Angeles, California • Gainesville, Florida • Oak Lawn, Illinois + 14 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Ustekinumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Belcesiran, Placebo; Drug · Other
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: La Jolla, California • Gainesville, Florida • Charleston, South Carolina

Conditions: Hypertension
Interventions: EnligHTN Renal Denervation, Sham; Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Jackson, Mississippi

Conditions: Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions: ZYNRELEF 200Mg-6Mg Extended-Release Solution; Drug
Lead sponsor: Dr. Yannis Raftopoulos; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Holyoke, Massachusetts

Conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions: Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Norovirus Prevention
Interventions: Norovirus Bivalent VLP Vaccine, Placebo (Saline); Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more

Conditions: Actinic Keratoses
Interventions: PEP005 (ingenol mebutate) Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 17
States / cities: Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more

Conditions: People With Identified Painful Trigger Points (Tp) Within the Soleus and Gastrocnemius Muscles Complex, Healthy Subjects or Volunteers
Interventions: Dry needling with electrical stimulation, Dry needling, Electrical stimulation, Sham; Procedure
Lead sponsor: University of Rhode Island; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kingston, Rhode Island

Conditions: Dyslipidaemia
Interventions: TAP311 capsules, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions: N-Acetyl Cysteine, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Erectile Dysfunction
Interventions: Tamsulosin and avanafil, Doxazosin and avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetic Neuropathy, Painful
Interventions: PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 32
States / cities: Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: ANG003 Dose A, ANG003 Dose B, Creon; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 24 more

Conditions: Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 208
States / cities: Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more

Conditions: Grief, Depressive Symptoms, Trauma, Psychological
Interventions: Accelerated Resolution Therapy; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 60 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD)
Interventions: Zeleciment Rostudirsen (DYNE-251), Placebo; Drug
Lead sponsor: Dyne Therapeutics; Industry
Eligibility: 4 Years to 18 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Hillsborough, North Carolina

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone, Placebo, Rivoglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 70
States / cities: Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more

Conditions: Social Anxiety Disorder
Interventions: Cannabidiol oral solution, Placebo; Drug
Lead sponsor: EmpowerPharm Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 17
States / cities: Encino, California • Lemon Grove, California • Los Alamitos, California + 14 more

Conditions: Alzheimer's Disease
Interventions: ST101, Placebo; Drug
Lead sponsor: Sonexa Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 27
States / cities: Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more

Search by objective public record fields.

VEST Venous Graft External Support Pivotal Study

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Study of Belcesiran in Patients With AATLD

EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Trigger Point Dry Needling With and Without Electrical Stimulation in Healthy Subjects

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

N-Acetyl Cysteine in Pathologic Skin Picking

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Accelerated Resolution Therapy for Complicated Grief

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease